Verastem’s Promising Phase 3 Trial in Ovarian Cancer: A Potential Game-Changer?

Verastem Inc ((VSTM)) announced an update on their ongoing clinical study.

Verastem Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator’s Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)’. The study aims to evaluate the safety and efficacy of the combination of avutometinib and defactinib compared to standard treatments chosen by investigators for patients with recurrent LGSOC who have previously undergone platinum-based therapy.

The study tests the experimental combination of the drugs avutometinib and defactinib, both administered orally, against a range of standard treatments including pegylated liposomal doxorubicin, paclitaxel, letrozole, and anastrozole. The goal is to determine if the combination therapy offers superior outcomes for patients.

This interventional study employs a randomized, crossover design with no masking, focusing on treatment as the primary purpose. It seeks to provide insights into the effectiveness of the new drug combination compared to existing treatment options.

The study began on October 2, 2023, with an estimated primary completion date in August 2025. The latest update was submitted on August 22, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might be available.

The outcome of this study could significantly influence Verastem Inc.’s stock performance and investor sentiment, as successful results may enhance the company’s competitive position in the oncology market. The involvement of prominent collaborators like the GOG Foundation and ENGOT underscores the study’s potential impact.

The study is currently recruiting, with further details accessible on the ClinicalTrials portal.